Medpace Holdings, a global CRO focused on drug and medical device development, filed on Friday with the SEC to raise up to $150 million in an initial public offering.
The Cincinnati, OH-based company was founded in 1992 and booked $332 million in sales for the 12 months ended March 31, 2016. It plans to list on the Nasdaq under the symbol MEDP. Medpace filed confidentially on March 15, 2016. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
